Genetisk variation i effekten af clopidogrel

Karl Emil Kristensen; Henrik Berg Rasmussen; Peter Riis Hansen

Genetisk variation i effekten af clopidogrel

Translated title of the contribution: Genetic variability in the efficacy of clopidogrel

Karl Emil Kristensen, Henrik Berg Rasmussen, Peter Riis Hansen

Department of Clinical Medicine

Abstract

Hepatic cytochrome P450 (CYP) bioactivation of clopidogrel is reduced in subjects with the CYP2C19*2 loss-of-function allele. This allele has been linked to an increased risk of stent thrombosis after percutaneous coronary intervention. In contrast to clopidogrel, the effect of newer antiplatelet agents, e.g., prasugrel and ticagrelor, is not dependent on CYP2C19. This review briefly outlines the current evidence for the value of CYP2C19 genotyping to guide antiplatelet therapy with clopidogrel. Prospective trials of new treatment algorithms are awaited before routine adoption of CYP2C19 genotyping for this purpose.

Translated title of the contribution	Genetic variability in the efficacy of clopidogrel
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	175
Issue number	11
Pages (from-to)	729-32
Number of pages	4
ISSN	0041-5782
Publication status	Published - 11 Mar 2013

Access to Document

http://ugeskriftet.dk/files/ugeskriftet.dk/artikel_5517.pdf

Cite this

@article{e059e1cc36e847c8bc905a31589f6366,

title = "Genetisk variation i effekten af clopidogrel",

abstract = "Hepatic cytochrome P450 (CYP) bioactivation of clopidogrel is reduced in subjects with the CYP2C19*2 loss-of-function allele. This allele has been linked to an increased risk of stent thrombosis after percutaneous coronary intervention. In contrast to clopidogrel, the effect of newer antiplatelet agents, e.g., prasugrel and ticagrelor, is not dependent on CYP2C19. This review briefly outlines the current evidence for the value of CYP2C19 genotyping to guide antiplatelet therapy with clopidogrel. Prospective trials of new treatment algorithms are awaited before routine adoption of CYP2C19 genotyping for this purpose.",

author = "Kristensen, {Karl Emil} and Rasmussen, {Henrik Berg} and Hansen, {Peter Riis}",

year = "2013",

month = mar,

day = "11",

language = "Dansk",

volume = "175",

pages = "729--32",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "11",

}

TY - JOUR

T1 - Genetisk variation i effekten af clopidogrel

AU - Kristensen, Karl Emil

AU - Rasmussen, Henrik Berg

AU - Hansen, Peter Riis

PY - 2013/3/11

Y1 - 2013/3/11

N2 - Hepatic cytochrome P450 (CYP) bioactivation of clopidogrel is reduced in subjects with the CYP2C19*2 loss-of-function allele. This allele has been linked to an increased risk of stent thrombosis after percutaneous coronary intervention. In contrast to clopidogrel, the effect of newer antiplatelet agents, e.g., prasugrel and ticagrelor, is not dependent on CYP2C19. This review briefly outlines the current evidence for the value of CYP2C19 genotyping to guide antiplatelet therapy with clopidogrel. Prospective trials of new treatment algorithms are awaited before routine adoption of CYP2C19 genotyping for this purpose.

AB - Hepatic cytochrome P450 (CYP) bioactivation of clopidogrel is reduced in subjects with the CYP2C19*2 loss-of-function allele. This allele has been linked to an increased risk of stent thrombosis after percutaneous coronary intervention. In contrast to clopidogrel, the effect of newer antiplatelet agents, e.g., prasugrel and ticagrelor, is not dependent on CYP2C19. This review briefly outlines the current evidence for the value of CYP2C19 genotyping to guide antiplatelet therapy with clopidogrel. Prospective trials of new treatment algorithms are awaited before routine adoption of CYP2C19 genotyping for this purpose.

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 175

SP - 729

EP - 732

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 11

ER -

Genetisk variation i effekten af clopidogrel

Abstract

Access to Document

Fingerprint

Cite this